Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666709 | 0.82 | TDP1 (0.53) | KDM4ETSHRPOLBNPSR1TDP1 | |
| SCHEMBL7414349 | 0.80 | KDM4E (0.56) | KDM4ETSHRPOLBNPSR1TDP1 | |
| SCHEMBL31059180 | 0.80 | KDM4E (0.68) | KDM4ETSHRPOLBNPSR1TDP1 | |
| SCHEMBL30086100 | 0.80 | KDM4E (0.58) | KDM4ETSHRPOLBNPSR1TDP1 | |
| SCHEMBL12819456 | 0.80 | KDM4E (0.68) | KDM4ETSHRPOLBNPSR1TDP1 | |
| SCHEMBL229256 | 0.80 | KDM4E (0.58) | KDM4ETSHRPOLBNPSR1TDP1 | |
| SCHEMBL31059181 | 0.80 | KDM4E (0.68) | KDM4ETSHRPOLBNPSR1TDP1 | |
| SCHEMBL10501002 | 0.79 | HRH1 (0.52) | KDM4ETSHRPOLBNPSR1TDP1 | |
| Hydrochloric Acid SCHEMBL29367467 | 0.78 | KDM4E (0.57) | KDM4ETSHRPOLBNPSR1TDP1 | |
| SCHEMBL9082173 | 0.77 | KDM4E (0.55) | KDM4ETSHRPOLBNPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362909-A2 | MAMMALIAN GENES INVOLVED IN INFECTION | Zirus, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2011008230-A2 | RAPAMYCIN DERIVATIVES AND ETHERS OF N-PROPANOLAMINES AND USES RELATED TO INFECTION | Zirus, Inc. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010039778-A2 | MAMMALIAN GENES INVOLVED IN INFECTION | Zirus, Inc. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-6200985-B1 | ADMINISTERING TO PREVENT ORGAN OR TISSUE TRANSPLANT REJECTION | NOVARTIS AG (CH) | 2001-03-13 | — | — | US | disclosed |
| EP-0734389-B1 | RAPAMYCIN DERIVATIVES USEFUL AS IMMUNOSUPPRESSANTS | NOVARTIS AG (CH) | 2000-03-29 | — | — | EP | disclosed |
| US-5985890-A | Rapamycin derivatives | NOVARTIS AG (CH) | 1999-11-16 | — | — | US | disclosed |
| US-5912253-A | 16-DEMETHOXY DERIVATIVES HAVING GREATER STABILITY AND BIOAVAILABILITY; FOR USE AS IMMUNOSUPPRESSANTS | NOVARTIS AG (CH) | 1999-06-15 | — | — | US | disclosed |
| EP-0833828-A1 | RAPAMYCIN DERIVATIVES | Novartis AG (CH) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996041807-A1 | RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 1996-12-27 | — | — | WO | disclosed |
| EP-0734389-A1 | RAPAMYCIN DERIVATIVES USEFUL AS IMMUNOSUPPRESSANTS | Novartis AG (CH) | 1996-10-02 | — | — | EP | disclosed |
| WO-1994025062-A1 | ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING RENIN INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-10 | — | — | WO | disclosed |
| EP-0300189-B1 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0617622-A1 | USE OF RENIN INHIBITORS FOR THE TREATMENT OF GLAUCOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-05 | — | — | EP | disclosed |
| EP-0573652-A1 | REMEDY FOR RENAL DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-15 | — | — | EP | disclosed |
| WO-1993012796-A1 | USE OF RENIN INHIBITORS FOR THE TREATMENT OF GLAUCOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-08 | — | — | WO | disclosed |
| US-5223489-A | Treatment of ypertension and heart failure | UJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5142048-A | Enzyme inhibitor; carbamoyl group-containing acids | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| US-5063208-A | Cardiovascular disorders, vision defects | ABBOTT LABORATORIES (US) | 1991-11-05 | — | — | US | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |